AbbVie Financial Model
Pharmaceuticals Company Financials Example (Free Excel Download)
AbbVie is a global, research-based biopharmaceutical company that discovers and delivers innovative medicines and aesthetic products.
professionals from Deloitte
Used by professionals from
About this model
This model evaluates AbbVie's sum-of-the-parts revenue trajectory and cash flow generation to determine if the rapid growth of its newer immunology assets (Skyrizi and Rinvoq) and recent acquisitions can successfully offset the revenue erosion from the Humira loss of exclusivity, ultimately informing an equity valuation and dividend sustainability assessment.
AbbVie is a global, research-based biopharmaceutical company that discovers and delivers innovative medicines and aesthetic products. The company was formed in 2013 following its separation from Abbott Laboratories and has since grown through organic pipeline development and major acquisitions, including Allergan, ImmunoGen, and Cerevel Therapeutics.
Business segments and approximate 2024 revenue contribution:
- Immunology (approx. 45%): Driven by Humira, Skyrizi, and Rinvoq.
- Neuroscience (approx. 15%): Driven by Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta.
- Aesthetics (approx. 10%): Driven by Botox Cosmetic and Juvederm.
- Oncology (approx. 10%): Driven by Imbruvica, Venclexta, and Elahere.
- Other Key Products / Eye Care (approx. 10%): Driven by Mavyret, Creon, and eye care products.
The business model is asset-light in physical manufacturing but highly capital-intensive regarding research and development and intellectual property acquisition. AbbVie holds a dominant competitive position in immunology and medical aesthetics, though it faces intense biosimilar competition for its legacy blockbuster, Humira. Recent major events include the 2023 US loss of exclusivity for Humira and the 2024 acquisitions of ImmunoGen ($10 billion) and Cerevel Therapeutics ($8.7 billion) to bolster the oncology and neuroscience pipelines.
The downloadable AbbVie financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsAbbVie financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $56.20B | $58.05B | $54.32B | $56.33B | $61.16B |
| Gross profit | $38.75B | $40.64B | $33.90B | $39.43B | $42.96B |
| Operating income | $17.92B | $18.12B | $12.76B | $9.14B | $15.07B |
| Net income | $11.54B | $11.84B | $4.86B | $4.28B | $4.23B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for AbbVie
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Immunology
- Segment name: Immunology
- Revenue driver formula: (Patient Volume x Market Share) x Net Price per Prescription
- Historical growth rate: Historically high single digits, but currently declining due to Humira erosion (segment down approx. 3% in 2024).
- Key growth levers and headwinds: Skyrizi and Rinvoq are capturing massive market share in psoriasis, Crohn's disease, and ulcerative colitis. The primary headwind is the steep volume and price erosion of Humira due to multiple US biosimilar entrants.
- Pricing dynamics: Highly rebated. Gross-to-net pricing is a major factor, with pharmacy benefit managers extracting significant rebates.
- Revenue recognition notes: Recognised upon delivery to wholesalers, net of estimated rebates, chargebacks, and discounts.
- Seasonality: Q1 is typically the weakest quarter due to the resetting of patient deductibles and Medicare Part D coverage gaps in the US.
Oncology
- Segment name: Oncology
- Revenue driver formula: Treated Patients x Duration of Therapy x Net Price
- Historical growth rate: Low to mid-single digits (approx. 12% operational growth in 2024).
- Key growth levers and headwinds: Venclexta and the newly acquired Elahere are driving growth. Imbruvica is facing severe headwinds from competitive BTK inhibitors and Medicare price negotiation pressures.
- Pricing dynamics: High list prices with lower rebate pressure compared to immunology, though Medicare Part D redesign impacts net pricing.
- Revenue recognition notes: Standard pharmaceutical recognition net of gross-to-net adjustments.
- Seasonality: Generally stable throughout the year.
Neuroscience
- Segment name: Neuroscience
- Revenue driver formula: Prescription Volume x Net Price (or Vials Sold x Price for Botox)
- Historical growth rate: High teens (approx. 16% to 19% growth in 2024).
- Key growth levers and headwinds: Vraylar for major depressive disorder and the migraine portfolio (Ubrelvy, Qulipta) are driving rapid volume growth. Botox Therapeutic remains a steady, high-margin cash cow.
- Pricing dynamics: Mix of buy-and-bill (Botox) and standard pharmacy benefit (oral migraine drugs).
- Revenue recognition notes: Standard gross-to-net accounting.
- Seasonality: Slight Q4 strength due to end-of-year insurance deductible utilisation.
Aesthetics
- Segment name: Aesthetics
- Revenue driver formula: Provider Volume x Vials/Syringes per Provider x Price
- Historical growth rate: Low single-digit decline recently (down approx. 4% in 2024).
- Key growth levers and headwinds: Highly sensitive to macroeconomic conditions and consumer discretionary spending. Botox Cosmetic is resilient, but dermal fillers (Juvederm) have faced significant pressure from a softer consumer environment.
- Pricing dynamics: Cash-pay market. No insurance reimbursement, meaning pricing is dictated by consumer demand and provider competition.
- Revenue recognition notes: Recognised upon shipment to medical spas and dermatology clinics.
- Seasonality: Stronger in Q2 and Q4 ahead of summer holidays and winter festivities.
Cost Structure
Variable Costs / COGS
- COGS includes raw materials, third-party manufacturing costs, royalty payments to partners, and the amortisation of acquired intangible assets.
- Gross margin range: GAAP gross margins are typically 68% to 71%. Adjusted gross margins (excluding intangible amortisation) range from 83% to 85%.
- Key input costs include active pharmaceutical ingredients and biologic manufacturing overheads.
- COGS scales linearly with volume, though product mix heavily influences the consolidated margin (e.g. Aesthetics has higher gross margins than partnered Oncology drugs).
Operating Expenses
- R&D: Typically 14% to 16% of adjusted revenue. It covers clinical trials, discovery research, and regulatory submissions. GAAP R&D is often much higher (up to 45% in 2024) due to massive upfront charges for acquired In-Process R&D (IPR&D) and milestone payments.
- SG&A: Typically 23% to 25% of adjusted revenue. This is heavily driven by the massive sales forces required for primary care and aesthetics, as well as direct-to-consumer television advertising for Skyrizi, Rinvoq, and Vraylar.
- Depreciation & Amortisation: Extremely high due to the Allergan, ImmunoGen, and Cerevel acquisitions. Intangible amortisation runs at several billion dollars annually and is excluded from non-GAAP metrics.
- Stock-Based Compensation: Typical for a large pharmaceutical company, running at approximately 1% to 2% of revenue.
- Restructuring / one-time charges: Frequent, driven by continuous M&A integration and periodic pipeline asset impairment charges (e.g. the $3.5 billion emraclidine impairment in 2024).
Margin Profile
- Adjusted Gross Margin: 83% to 85%.
- Adjusted Operating Margin: 45% to 48% (GAAP operating margins are often severely depressed by IPR&D and amortisation, sometimes falling below zero in specific quarters).
- Adjusted Net Margin: 30% to 35%.
- Margin trend: Stable to slightly compressing as high-margin Humira is replaced by partnered or lower-margin growth products, though management aggressively manages SG&A to protect the operating margin.
Balance Sheet Structure
- Total assets are approximately $135 billion to $140 billion.
- Key asset categories are Goodwill and Intangible Assets, which represent the vast majority of the balance sheet due to the historical Allergan acquisition and recent bolt-on deals.
- Goodwill & intangibles represent over 65% of total assets.
- Working capital profile:
- Days Sales Outstanding (DSO): 55 to 65 days.
- Days Inventory Outstanding (DIO): 80 to 100 days (biologics require long manufacturing lead times).
- Days Payable Outstanding (DPO): 60 to 75 days.
- Net working capital as a % of revenue is typically low to slightly positive.
- PP&E consists of highly specialised biologic manufacturing facilities and research laboratories. Useful lives range from 10 to 20 years for facilities.
- Right-of-use assets are immaterial relative to the massive intangible asset base.
Capital Expenditure & Investment
- Capex as a % of revenue is very low, typically ranging from 1.5% to 2.0%.
- Maintenance capex accounts for roughly 60% of total capex, with the remainder dedicated to expanding biologic manufacturing capacity.
- Capitalised software is immaterial.
- M&A pattern: AbbVie is a transformational and serial bolt-on acquirer. It relies heavily on M&A to replenish its pipeline (Allergan for Aesthetics/Neuroscience, Pharmacyclics for Oncology, ImmunoGen for ADCs, Cerevel for Neuroscience).
- Typical acquisition multiples are high, often based on peak sales multiples of unapproved pipeline assets rather than trailing EBITDA.
Debt & Capital Structure
- Total debt is approximately $60 billion to $65 billion, with net debt around $50 billion to $55 billion.
- Debt/EBITDA ratio (adjusted) targets the 2.0x to 2.5x range, though it temporarily spikes following major acquisitions.
- Credit rating is typically BBB+ or equivalent.
- Key debt instruments are unsecured senior notes. The company issued $15 billion in notes in 2024 to fund the ImmunoGen and Cerevel deals.
- Maturity profile is well-laddered, with average maturities extending beyond 10 years.
- Interest rate profile is predominantly fixed-rate bonds.
- Share repurchase programme is active but secondary to the dividend and debt paydown. The company repurchased approximately $1.3 billion in 2024.
- Dividend policy is a core pillar of the investment thesis. AbbVie is a Dividend Aristocrat with a yield typically between 3.5% and 4.5% and an annual growth rate of 4% to 6%.
Cash Flow Characteristics
- Operating cash flow conversion is exceptionally strong. OCF / Net Income is often greater than 2.0x on a GAAP basis because of the massive non-cash intangible amortisation and IPR&D charges.
- Free cash flow margin (FCF / Revenue) typically ranges from 35% to 40%.
- Major non-cash items bridging net income to OCF include depreciation, intangible asset amortisation, acquired IPR&D, and deferred income taxes.
- Working capital is a minor use of cash as the business grows.
- Capex intensity is very low, allowing almost all operating cash flow to convert to free cash flow.
- Cash tax rate is generally aligned with the adjusted effective tax rate (approx. 15% to 20%), which is lower than the US statutory rate due to manufacturing in favorable tax jurisdictions like Puerto Rico and Ireland.
Sheet Structure
- Assumptions: Hardcoded drivers for segment growth, gross-to-net pricing, margins, tax rates, and WACC.
- Revenue Build: Detailed build by segment (Immunology, Oncology, Neuroscience, Aesthetics, Other). Must include specific line items for Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox (Therapeutic and Cosmetic), and Juvederm.
- Income Statement: GAAP to Non-GAAP bridge. Must explicitly separate Intangible Amortisation and Acquired IPR&D from standard COGS and R&D.
- Balance Sheet: Standard format, highlighting Goodwill, Intangible Assets, and Short/Long-Term Debt.
- Cash Flow Statement: Operating, Investing, and Financing cash flows. Must link the massive non-cash amortisation add-backs from the Income Statement.
- Debt Schedule: Tranche-by-tranche debt build, tracking the $15 billion 2024 issuance and maturity ladder, calculating interest expense.
- Working Capital: Schedules for Accounts Receivable, Inventory, and Accounts Payable based on DSO, DIO, and DPO.
- DCF Valuation: Unlevered free cash flow build, terminal value calculation, and implied share price.
Key Financial Relationships
- Immunology Revenue = Humira Revenue + Skyrizi Revenue + Rinvoq Revenue
- Humira Revenue = Prior Year Humira Revenue x (1 - Estimated Biosimilar Erosion Rate)
- Aesthetics Revenue = Botox Cosmetic Revenue + Juvederm Revenue + Other Aesthetics
- GAAP COGS = Adjusted COGS + Intangible Asset Amortisation
- GAAP R&D = Adjusted R&D + Acquired IPR&D and Milestones
- Adjusted Gross Profit = Total Revenue - Adjusted COGS
- Adjusted Operating Income = Adjusted Gross Profit - Adjusted SG&A - Adjusted R&D
- Interest Expense = Average Total Debt Balance x Weighted Average Interest Rate
- Free Cash Flow = Operating Cash Flow - Capital Expenditures
- Dividends Paid = Shares Outstanding x Annual Dividend Per Share
Cross-Sheet Dependencies
- The Revenue Build feeds the top line of the Income Statement.
- The Income Statement generates Net Income, which is the starting point for the Cash Flow Statement.
- Non-cash charges (Amortisation, IPR&D) from the Income Statement must flow directly into the Cash Flow Statement as positive add-backs.
- The Cash Flow Statement determines the ending cash balance and debt paydown capacity, which feeds the Debt Schedule and Balance Sheet.
- The Debt Schedule calculates interest expense, which loops back to the Income Statement. (To avoid circularity, interest expense should be calculated on the beginning-of-period debt balance).
Sign Convention
- Revenues, assets, and cash inflows are represented as positive numbers.
- Expenses, liabilities, and cash outflows (including capex, dividends, and share repurchases) are represented as negative numbers in the cash flow statement and build schedules.
- Margins and growth rates are represented as positive percentages unless indicating a decline (e.g. Humira growth rate is negative).
Things Most Likely to Go Wrong
- Failing to separate GAAP from Non-GAAP (Adjusted) metrics. AbbVie's GAAP earnings are heavily distorted by intangible amortisation and IPR&D. The model must forecast on an adjusted basis to be meaningful.
- Underestimating the speed of Humira's revenue decline. Biosimilar erosion curves are steep; modeling a linear decline will overstate near-term cash flows.
- Lumping Botox Therapeutic and Botox Cosmetic together. They sit in entirely different reporting segments (Neuroscience vs. Aesthetics) and have different growth drivers and reimbursement models.
- Ignoring the massive IPR&D charges. While excluded from adjusted EPS, these are real cash outflows that impact the balance sheet and debt levels.
- Miscalculating the tax rate. The GAAP tax rate can look bizarre (e.g. 99% in Q4 2024 due to impairment charges). The model must use the adjusted effective tax rate of approximately 16% to 20%.
- Overestimating capex. As an asset-light biopharma company, capex is minimal. Modeling capex as a standard percentage of asset growth will destroy free cash flow accuracy.
- Forgetting the dividend burden. AbbVie pays out over $10 billion annually in dividends. This must be accurately modeled to understand debt paydown capacity.
- Double-counting pipeline revenue. Acquired assets like Elahere and emraclidine must be modeled carefully, noting that emraclidine recently suffered a $3.5 billion impairment due to trial failures.
Validation Checks
- Adjusted Gross Margin should remain between 83% and 85%. Flag if it drops below 80%.
- Adjusted Operating Margin should remain between 45% and 48%.
- Capex as a % of revenue must not exceed 2.5%.
- Total Revenue for 2025 should exceed the 2024 base of $56.3 billion, validating management's guidance of a return to growth.
- Debt/EBITDA should trend downwards towards 2.0x over the forecast period as the 2024 acquisition debt is paid down.
- The Balance Sheet must balance perfectly in every forecast year (Total Assets = Total Liabilities + Equity).
- Dividend payout ratio (Dividends / Adjusted Net Income) should remain between 40% and 50%.
- Free Cash Flow conversion (FCF / Adjusted Net Income) should be approximately 1.0x.
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Skyrizi Revenue Growth | 30.0 | % | Continued rapid market share capture in IBD and psoriasis. |
| Rinvoq Revenue Growth | 25.0 | % | Strong uptake across multiple immunology indications. |
| Humira Revenue Decline | -35.0 | % | Steep ongoing erosion from US biosimilar competition. |
| Aesthetics Segment Growth | 2.0 | % | Sluggish consumer environment impacting Juvederm and Botox Cosmetic. |
| Adjusted Gross Margin | 83.8 | % | Based on 2024 actual adjusted gross margin. |
| Adjusted SG&A Margin | 23.6 | % | Based on 2024 actual adjusted SG&A margin. |
| Adjusted R&D Margin | 15.1 | % | Based on 2024 actual adjusted R&D margin. |
| Adjusted Effective Tax Rate | 20.2 | % | Based on 2024 actual adjusted tax rate. |
| Capex as % of Revenue | 1.5 | % | Historical average for AbbVie's asset-light manufacturing footprint. |
| Cost of Debt (Interest Rate) | 4.5 | % | Estimated weighted average interest rate on existing senior notes. |
| Shares Outstanding | 1,766 | Millions | Based on Q3 2024 reported diluted share count. |
| Annual Dividend Per Share | 6.56 | USD | Based on the 2024 declared quarterly rate of $1.64 annualised. |
| WACC | 7.5 | % | Standard discount rate for large-cap, diversified pharmaceutical companies. |
| Terminal Growth Rate | 1.0 | % | Conservative long-term growth rate accounting for perpetual patent cliffs. |
Data Sources & Benchmarks
- SEC Filings: AbbVie Investor Relations page and SEC EDGAR (10-K, 10-Q, 8-K earnings releases).
- Key Peers: Johnson & Johnson (JNJ), Merck (MRK), Pfizer (PFE), Eli Lilly (LLY), Bristol-Myers Squibb (BMY).
- Industry Data: EvaluatePharma for consensus pipeline estimates and patent expiry dates; IQVIA for weekly prescription volume data (TRx/NRx) for Skyrizi, Rinvoq, and Humira.
- Consensus Estimates: Bloomberg or FactSet for sell-side consensus on specific asset peak sales.
Sources
Do more with the AbbVie model
Frequently asked
What kind of company is AbbVie and what are its main business areas?+
AbbVie is a global, research-based biopharmaceutical company focused on discovering and delivering innovative medicines and aesthetic products. Its primary business segments include Immunology, Neuroscience, Aesthetics, and Oncology, driven by a portfolio of key products and recent acquisitions.
What are the key revenue drivers for AbbVie, especially considering recent market changes?+
AbbVie's revenue is primarily driven by its immunology portfolio, including Skyrizi and Rinvoq, along with products in Neuroscience, Aesthetics, and Oncology. The rapid growth of newer immunology assets and recent acquisitions are crucial for offsetting revenue erosion from the Humira loss of exclusivity.
What is a key assumption regarding capital expenditure in the AbbVie financial model?+
The financial model assumes a very low capital expenditure as a percentage of revenue, typically ranging from 1.5% to 2.0%. This reflects AbbVie's asset-light physical manufacturing model, with maintenance capex and biologic manufacturing capacity expansion being the main components.
What is the primary goal of the financial model for AbbVie's valuation?+
The financial model's primary goal is to evaluate AbbVie's sum-of-the-parts revenue trajectory and cash flow generation. This analysis ultimately informs an equity valuation and an assessment of the company's dividend sustainability.
What is the forecast horizon for the downloadable AbbVie financial model?+
The downloadable Excel financial model for AbbVie provides a forecast horizon spanning from Fiscal Year 2026 through Fiscal Year 2030. This model is designed to analyze the company's future financial performance and cash flow generation.
How does AbbVie's business model address the challenge of patent expirations for its blockbuster drugs?+
AbbVie's business model is highly reliant on continuous research and development and strategic acquisitions to replenish its pipeline. This strategy, exemplified by major deals like Allergan and ImmunoGen, aims to introduce new innovative medicines and offset revenue erosion from legacy blockbusters like Humira facing biosimilar competition.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Pharmaceuticals Company Financial Models
Browse another company in the same sector.
Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics, focusing on areas of high unmet medical need.
Biogen
Biogen is a global biotechnology company that discovers, develops, and delivers therapies for neurological, immunological, and rare diseases, including multiple sclerosis and Alzheimer's treatments.
Bristol Myers Squibb
Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercialises innovative medicines in areas of unmet medical need.
Incyte
Incyte Corporation is a global commercial-stage biopharmaceutical company focused on the discovery, development, and commercialisation of proprietary therapeutics, primarily in haematology, oncology, and inflammation and autoimmunity (IAI).
Johnson & Johnson
Johnson & Johnson is a diversified global healthcare leader engaged in the research, development, manufacture, and sale of pharmaceutical products and medical devices.
Lilly (Eli)
Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and markets human medicines, with a dominant focus on cardiometabolic diseases, oncology, immunology, and neuroscience.
Merck & Co.
Merck is a global healthcare company, known as MSD outside the US and Canada, that discovers, develops, and provides innovative prescription medicines, biologic therapies, vaccines, and animal health products.
Explore more Healthcare financial model templates.
